Cargando…

Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis

BACKGROUND: Hypercoagulability in lung cancer patients is associated with a high incidence of mortality and morbidity in the world. Therefore, this meta‐analysis aimed to explore the correlation of the basic coagulation abnormalities in lung cancer patients compared with the control. METHOD: PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayleyegn, Biruk, Adane, Tiruneh, Getawa, Solomon, Aynalem, Melak, Kifle, Zemen Demelash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279983/
https://www.ncbi.nlm.nih.gov/pubmed/35719003
http://dx.doi.org/10.1002/jcla.24550
_version_ 1784746531026370560
author Bayleyegn, Biruk
Adane, Tiruneh
Getawa, Solomon
Aynalem, Melak
Kifle, Zemen Demelash
author_facet Bayleyegn, Biruk
Adane, Tiruneh
Getawa, Solomon
Aynalem, Melak
Kifle, Zemen Demelash
author_sort Bayleyegn, Biruk
collection PubMed
description BACKGROUND: Hypercoagulability in lung cancer patients is associated with a high incidence of mortality and morbidity in the world. Therefore, this meta‐analysis aimed to explore the correlation of the basic coagulation abnormalities in lung cancer patients compared with the control. METHOD: PubMed, Scopus, and other sources were employed to identify eligible studies. The outcome variable was expressed using mean ± standard deviation (SD). Heterogeneity among studies and publication bias were evaluated. The quality of included studies was also assessed based on Newcastle–Ottawa Scale checklist. RESULT: Finally, through a total of eight studies, prolonged prothrombin time (PT; standard mean difference [SMD]: 1.29; 95% CI: 0.47–2.11), plasma D‐dimer value (SMD 3.10; 95% CI 2.08–4.12), fibrinogen (SMD 2.18; 95% CI:1.30–3.06), and platelet (PLT) count (SMD 1.00; 95% CI 0.84–1.16) were significantly higher in lung cancer patients when compared with the control group. The single‐arm meta‐analysis also showed that compared with control, lung cancer patients had high pooled PT 13.7 (95% CI:12.2–15.58) versus 11.79 (95% CI = 10.56–13.02), high D‐dimer 275.99 (95% CI:172.9–11735.9) versus 0.2 (95% CI:0.20–0.37), high plasma fibrinogen 5.50 (95% CI:4.21–6.79) versus 2.5 (95% CI:2.04–2.91), and high PLT count 342.3 (95% CI:236.1–448.5) versus 206.6 (95% CI:176.4–236.7). CONCLUSION: In conclusion, almost all the coagulation abnormalities were closely associated with lung cancer, and hence coagulation indexes provide an urgent clue for early diagnosis and timely management.
format Online
Article
Text
id pubmed-9279983
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92799832022-07-15 Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis Bayleyegn, Biruk Adane, Tiruneh Getawa, Solomon Aynalem, Melak Kifle, Zemen Demelash J Clin Lab Anal Review Essays BACKGROUND: Hypercoagulability in lung cancer patients is associated with a high incidence of mortality and morbidity in the world. Therefore, this meta‐analysis aimed to explore the correlation of the basic coagulation abnormalities in lung cancer patients compared with the control. METHOD: PubMed, Scopus, and other sources were employed to identify eligible studies. The outcome variable was expressed using mean ± standard deviation (SD). Heterogeneity among studies and publication bias were evaluated. The quality of included studies was also assessed based on Newcastle–Ottawa Scale checklist. RESULT: Finally, through a total of eight studies, prolonged prothrombin time (PT; standard mean difference [SMD]: 1.29; 95% CI: 0.47–2.11), plasma D‐dimer value (SMD 3.10; 95% CI 2.08–4.12), fibrinogen (SMD 2.18; 95% CI:1.30–3.06), and platelet (PLT) count (SMD 1.00; 95% CI 0.84–1.16) were significantly higher in lung cancer patients when compared with the control group. The single‐arm meta‐analysis also showed that compared with control, lung cancer patients had high pooled PT 13.7 (95% CI:12.2–15.58) versus 11.79 (95% CI = 10.56–13.02), high D‐dimer 275.99 (95% CI:172.9–11735.9) versus 0.2 (95% CI:0.20–0.37), high plasma fibrinogen 5.50 (95% CI:4.21–6.79) versus 2.5 (95% CI:2.04–2.91), and high PLT count 342.3 (95% CI:236.1–448.5) versus 206.6 (95% CI:176.4–236.7). CONCLUSION: In conclusion, almost all the coagulation abnormalities were closely associated with lung cancer, and hence coagulation indexes provide an urgent clue for early diagnosis and timely management. John Wiley and Sons Inc. 2022-06-19 /pmc/articles/PMC9279983/ /pubmed/35719003 http://dx.doi.org/10.1002/jcla.24550 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Essays
Bayleyegn, Biruk
Adane, Tiruneh
Getawa, Solomon
Aynalem, Melak
Kifle, Zemen Demelash
Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis
title Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis
title_full Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis
title_fullStr Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis
title_full_unstemmed Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis
title_short Coagulation parameters in lung cancer patients: A systematic review and meta‐analysis
title_sort coagulation parameters in lung cancer patients: a systematic review and meta‐analysis
topic Review Essays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279983/
https://www.ncbi.nlm.nih.gov/pubmed/35719003
http://dx.doi.org/10.1002/jcla.24550
work_keys_str_mv AT bayleyegnbiruk coagulationparametersinlungcancerpatientsasystematicreviewandmetaanalysis
AT adanetiruneh coagulationparametersinlungcancerpatientsasystematicreviewandmetaanalysis
AT getawasolomon coagulationparametersinlungcancerpatientsasystematicreviewandmetaanalysis
AT aynalemmelak coagulationparametersinlungcancerpatientsasystematicreviewandmetaanalysis
AT kiflezemendemelash coagulationparametersinlungcancerpatientsasystematicreviewandmetaanalysis